@prefix : <http://semanticscholar.org/cv-research/> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix fhir_link: <http://hl7.org/fhir/link/> .
@prefix ncit: <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sso: <http://semanticscholar.org/cv-research/> .
@prefix whocv: <http://semanticscholar.org/cv-research/WHO#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<http://fhircat.org/cord-19/metadata/697b9d764f13648fa38faa8d93fefde6049d6517> fhir_link: <https://fhircat.org/cord-19/fhir/Commercial/697b9d764f13648fa38faa8d93fefde6049d6517> ;
    dc:abstract "Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses." ;
    dc:creator "['Elshabrawy, Hatem A.', 'Coughlin, Melissa M.', 'Baker, Susan C.', 'Prabhakar, Bellur S.']" ;
    dc:identifier <http://dx.doi.org/10.1371/journal.pone.0050366>,
        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503966>,
        <https://www.ncbi.nlm.nih.gov/pubmed/23185609> ;
    dc:issued "2012-01-01"^^xsd:date ;
    dc:license "CC BY" ;
    dc:title "Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing" ;
    sso:has_full_text "True" ;
    sso:journal "PLoS One" ;
    sso:sha "697b9d764f13648fa38faa8d93fefde6049d6517" ;
    sso:source_x "PMC" .